


NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the July 2013 NCCN Trends™ Survey, which focused on Metastatic Castrate Resistant Prostate Cancer. This survey was sent to U.S. and International users of NCCN.org.


DEMOGRAPHICS

Distribution of Respondent Types (n = 1,083)




Note: Percentages may not total 100 because of rounding.

Q1. Do you treat patients with metastatic castrate resistant prostate cancer (mCRPC)? (n = 1,083)




Q2. Please select from the following agents, both approved and in development, of which you are currently familiar for the treatment of mCRPC. Please select all that apply. (n = 707)



Q2. Please select from the following agents, both approved and in development, of which you are currently familiar for the treatment of mCRPC. Please select all that apply.



By Geography

- US Midwest
- US Northeast
- US South
- US West
- Europe
- Latin America
- Asia
- Other Non-US



Q2. Please select from the following agents, both approved and in development, of which you are currently familiar for the treatment of mCRPC. Please select all that apply.


By Practice Size



Q2. Please select from the following agents, both approved and in development, of which you are currently familiar for the treatment of mCRPC. Please select all that apply.

By Practice Setting


■ Academic Setting
 ■ Community Setting




Q2. Please select from the following agents, both approved and in development, of which you are currently familiar for the treatment of mCRPC. Please select all that apply.

By Specialty

- Medical Oncology
- Radiation Oncology
- Surgical Oncology
- Hematology or Bone Marrow Transplant
- Internal Medicine
- General Surgery
- Other




Q3. Based on information currently available, how likely are you to utilize the following agents if granted FDA approval?



Q3. Based on information currently available, how likely are you to utilize the following agents if granted FDA approval?

By Geography

- Extremely Disinterested
- Disinterested
- Neutral
- Interested
- Extremely Interested




Continued on Page 10

Q3. Based on information currently available, how likely are you to utilize the following agents if granted FDA approval?

By Geography




Continued from Page 9



Q3. Based on information currently available, how likely are you to utilize the following agents if granted FDA approval?

By Practice Size


- Extremely Disinterested
- Disinterested
- Neutral
- Interested
- Extremely Interested



Q3. Based on information currently available, how likely are you to utilize the following agents if granted FDA approval?

By Practice Setting


- Extremely Disinterested
- Disinterested
- Neutral
- Interested
- Extremely Interested




Q3. Based on information currently available, how likely are you to utilize the following agents if granted FDA approval?

By Specialty

- Extremely Disinterested
- Disinterested
- Neutral
- Interested
- Extremely Interested





Q4. Focusing solely on the patients you have seen in the past month with symptomatic mCRPC, what percent would you estimate have the following metastatic disease sites?



Q4. Focusing solely on the patients you have seen in the past month with symptomatic mCRPC, what percent would you estimate have the following metastatic disease sites?


By Geography




Continued on Page 16

Q4. Focusing solely on the patients you have seen in the past month with symptomatic mCRPC, what percent would you estimate have the following metastatic disease sites?

By Geography





Continued from Page 15





Q4. Focusing solely on the patients you have seen in the past month with symptomatic mCRPC, what percent would you estimate have the following metastatic disease sites?

By Practice Size





Q4. Focusing solely on the patients you have seen in the past month with symptomatic mCRPC, what percent would you estimate have the following metastatic disease sites?

By Practice Setting



Q4. Focusing solely on the patients you have seen in the past month with symptomatic mCRPC, what percent would you estimate have the following metastatic disease sites?


By Specialty




Continued on Page 20

Q4. Focusing solely on the patients you have seen in the past month with symptomatic mCRPC, what percent would you estimate have the following metastatic disease sites?


By Specialty



Continued from Page 19





Q5. Of the patients you have seen in the past month with symptomatic mCRPC and bone metastases only, what percent would you estimate are currently being treated with each of the following treatment options?



Q5. Of the patients you have seen in the past month with symptomatic mCRPC and bone metastases only, what percent would you estimate are currently being treated with each of the following treatment options?


By Geography




Continued on Page 23

Q5. Of the patients you have seen in the past month with symptomatic mCRPC and bone metastases only, what percent would you estimate are currently being treated with each of the following treatment options?

By Geography




Continued from Page 22




Continued on Page 24

Q5. Of the patients you have seen in the past month with symptomatic mCRPC and bone metastases only, what percent would you estimate are currently being treated with each of the following treatment options?

By Geography





Continued from Page 23





Q5. Of the patients you have seen in the past month with symptomatic mCRPC and bone metastases only, what percent would you estimate are currently being treated with each of the following treatment options?

By Practice Size





Q5. Of the patients you have seen in the past month with symptomatic mCRPC and bone metastases only, what percent would you estimate are currently being treated with each of the following treatment options?

By Practice Setting



Q5. Of the patients you have seen in the past month with symptomatic mCRPC and bone metastases only, what percent would you estimate are currently being treated with each of the following treatment options?


By Specialty




Continued on Page 28

Q5. Of the patients you have seen in the past month with symptomatic mCRPC and bone metastases only, what percent would you estimate are currently being treated with each of the following treatment options?

By Specialty




Continued from Page 27




Continued on Page 29

Q5. Of the patients you have seen in the past month with symptomatic mCRPC and bone metastases only, what percent would you estimate are currently being treated with each of the following treatment options?

By Specialty



Continued from Page 28



NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an **NCCN Trends™** survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Christine MacCracken, MSHEd, BSN
Senior Director, Business Insights
215.690.0557
maccracken@nccn.org

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 23 of the world's leading cancer centers, is dedicated to improving the quality, effectiveness, and efficiency of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.



National
Comprehensive
Cancer
Network®

275 Commerce Drive • Suite 300
Fort Washington, PA, 19034
Telephone: 215.690.0300
Fax: 215.690.0280

NCCN.org - For Clinicians • NCCN.org/patients - For Patients

*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.